Despite global efforts to reduce childhood undernutrition, current interventions have had little impact on stunting and wasting, and the mechanisms underlying growth faltering are poorly understood. There is a clear need to distinguish populations of children most likely to benefit from any given intervention and to develop tools to monitor response to therapy prior to the development of morbid sequelae. In resource-limited settings, environmental enteric dysfunction (EED) is common among children, contributing to malnutrition and increasing childhood morbidity and mortality risk. In addition to EED, early alterations in the gut microbiota can adversely affect growth through nutrient malabsorption, altered metabolism, gut inflammation, and dysregulation of the growth hormone axis. We examined the evidence linking EED and the gut microbiome to growth faltering and explored novel biomarkers to identify subgroups of children at risk of malnutrition due to underlying pathology. These and other biomarkers could be used to identify specific groups of children at risk of malnutrition and monitor response to targeted interventions.

1.
Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al: Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013;382: 427–451.
2.
UNICEF-WHO-World Bank Group: Joint Child Malnutrition Estimates – Levels and Trends. 2016. http://www.who.int/nutgrowthdb/estimates2015/en/.
3.
Olofin I, McDonald CM, Ezzati M, Flaxman S, Black RE, Fawzi WW, et al: Associations of suboptimal growth with all-cause and cause-specific mortality in children under five years: a pooled analysis of ten prospective studies. PLoS One 2013;8:e64636.
4.
Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, et al: Maternal and child undernutrition: consequences for adult health and human capital. Lancet 2008;371: 340–357.
5.
Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B, et al: Developmental potential in the first 5 years for children in developing countries. Lancet 2007;369: 60–70.
6.
Guerrant RL, DeBoer MD, Moore SR, Scharf RJ, Lima AA: The impoverished gut – a triple burden of diarrhoea, stunting and chronic disease. Nat Rev Gastroenterol Hepatol 2013;10: 220–229.
7.
Salam RA, MacPhail C, Das JK, Bhutta ZA: Effectiveness of micronutrient powders (MNP) in women and children. BMC Public Health 2013;13(suppl 3):S22.
8.
Bhutta ZA, Das JK, Rizvi A, Gaffey MF, Walker N, Horton S, et al: Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? Lancet 2013;382: 452–477.
9.
Dewey KG, Adu-Afarwuah S: Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries. Matern Child Nutr 2008;4(suppl 1):24–85.
10.
Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, et al: Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clin Infect Dis 2014;59(suppl 4):S207–S212.
11.
Brown EM, Wlodarska M, Willing BP, Vonaesch P, Han J, Reynolds LA, et al: Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model. Nat Commun 2015;6: 7806.
12.
Tickell KD, Walson JL: Nutritional enteric failure: neglected tropical diseases and childhood stunting. PLoS Negl Trop Dis 2016;10:e0004523.
13.
Gordon JI, Dewey KG, Mills DA, Medzhitov RM: The human gut microbiota and undernutrition. Sci Transl Med 2012;4: 137ps112.
14.
Prendergast A, Kelly P: Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg 2012;86: 756–763.
15.
Humphrey JH: Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009;374: 1032–1035.
16.
Bourke CD, Berkley JA, Prendergast AJ: Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol 2016;37: 386–398.
17.
Korpe PS, Petri WA Jr: Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 2012;18: 328–336.
18.
Watanabe K, Petri WA Jr: Environmental enteropathy: elusive but significant subclinical abnormalities in developing countries. EBioMedicine 2016;10: 25–32.
19.
Schwarzer M, Makki K, Storelli G, Machuca-Gayet I, Srutkova D, Hermanova P, et al: Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition. Science 2016;351: 854–857.
20.
Fazeli PK, Klibanski A: Determinants of GH resistance in malnutrition. J Endocrinol 2014;220:R57–R65.
21.
Veitch AM, Kelly P, Zulu IS, Segal I, Farthing MJ: Tropical enteropathy: a T-cell-mediated crypt hyperplastic enteropathy. Eur J Gastroenterol Hepatol 2001;13: 1175–1181.
22.
Lunn PG, Northrop-Clewes CA, Downes RM: Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. Lancet 1991;338: 907–910.
23.
Faubion W, Camilleri M, Murray J, Kelly P, Amadi B, Kosek M, et al: Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged 5 years exposed to poor sanitation and hygiene. BMJ Global Health 2016;1:e000066.
24.
Brewster DR, Manary MJ, Menzies IS, O’Loughlin EV, Henry RL: Intestinal permeability in kwashiorkor. Arch Dis Child 1997;76: 236–241.
25.
Denno DM, VanBuskirk K, Nelson ZC, Musser CA, Hay Burgess DC, Tarr PI: Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: a systematic review. Clin Infect Dis 2014;59(suppl 4):S213–S219.
26.
Guerrant RL, Leite AM, Pinkerton R, Medeiros PH, Cavalcante PA, DeBoer M, et al: Biomarkers of environmental enteropathy, inflammation, stunting, and impaired growth in children in northeast Brazil. PLoS One 2016;11:e0158772.
27.
Tigas S, Tsatsoulis A: Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol 2012;25: 37–44.
28.
Prendergast AJ, Rukobo S, Chasekwa B, Mutasa K, Ntozini R, Mbuya MN, et al: Stunting is characterized by chronic inflammation in Zimbabwean infants. PLoS One 2014;9: e86928.
29.
Kosek M, Haque R, Lima A, Babji S, Shrestha S, Qureshi S, et al: Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am J Trop Med Hyg 2013;88: 390–396.
30.
Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, et al: Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine 2015;2: 1759–1766.
31.
Peterson KM, Buss J, Easley R, Yang Z, Korpe PS, Niu F, et al: REG1B as a predictor of childhood stunting in Bangladesh and Peru. Am J Clin Nutr 2013;97: 1129–1133.
32.
Campbell DI, Elia M, Lunn PG: Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J Nutr 2003;133: 1332–1338.
33.
Kosek MN, Mduma E, Kosek PS, Lee GO, Svensen E, Pan WK, et al: Plasma tryptophan and the kynurenine-tryptophan ratio are associated with the acquisition of statural growth deficits and oral vaccine underperformance in populations with environmental enteropathy. Am J Trop Med Hyg 2016;95: 928–937.
34.
Mericq V, De Luca F, Hernandez MI, Pena V, Rossel K, Garcia M, et al: Serum fibroblast growth factor 21 levels are inversely associated with growth rates in infancy. Horm Res Paediatr 2014;82: 324–331.
35.
Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA: Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008;8: 77–83.
36.
Wu S, Levenson A, Kharitonenkov A, De Luca F: Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem 2012;287: 26060–26067.
37.
Kubicky RA, Wu S, Kharitonenkov A, De Luca F: Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology 2012;153: 2287–2295.
38.
Arndt MB, Mahfuz M, Ahmed T, Haque R, Gazi MA, John-Stewart GC, Denno DM, Richardson BA, Scarlett JM, Walson JL: Fibroblast growth factor 21 as a biomarker of nutrition responsiveness. Poster presented at the 3rd International Conference on Nutrition & Growth, March 17–19, 2016, Vienna, Austria. Abstract No. NGC16-0490.
39.
Rodriguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al: The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 2015;26: 26050.
40.
Planer JD, Peng Y, Kau AL, Blanton LV, Ndao IM, Tarr PI, et al: Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice. Nature 2016;534: 263–266.
41.
Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI: Human nutrition, the gut microbiome and the immune system. Nature 2011;474: 327–336.
42.
Subramanian S, Blanton LV, Frese SA, Charbonneau M, Mills DA, Gordon JI: Cultivating healthy growth and nutrition through the gut microbiota. Cell 2015;161: 36–48.
43.
Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, et al: Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 2014;510: 417–421.
44.
Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, et al: Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013;339: 548–554.
45.
Gough EK, Stephens DA, Moodie EE, Prendergast AJ, Stoltzfus RJ, Humphrey JH, et al: Linear growth faltering in infants is associated with Acidaminococcus sp. and community-level changes in the gut microbiota. Microbiome 2015;3: 24.
46.
Blanton LV, Charbonneau MR, Salih T, Barratt MJ, Venkatesh S, Ilkaveya O, et al: Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science 2016;351.
47.
Ohlsson C, Sjogren K: Effects of the gut microbiota on bone mass. Trends Endocrinol Metab 2015;26: 69–74.
48.
Blanton LV, Barratt MJ, Charbonneau MR, Ahmed T, Gordon JI: Childhood undernutrition, the gut microbiota, and microbiota-directed therapeutics. Science 2016;352: 1533.
49.
De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99: 643–650.
50.
Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Sears MR, et al: Infant gut microbiota and the hygiene hypothesis of allergic disease: impact of household pets and siblings on microbiota composition and diversity. Allergy Asthma Clin Immunol 2013;9: 15.
51.
Donowitz JR, Haque R, Kirkpatrick BD, Alam M, Lu M, Kabir M, et al: Small intestine bacterial overgrowth and environmental enteropathy in Bangladeshi children. MBio 2016;7: e02102-15.
52.
Charbonneau MR, O’Donnell D, Blanton LV, Totten SM, Davis JC, Barratt MJ, et al: Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 2016;164: 859–871.
53.
Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al: Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015;149: 223–237.
54.
Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al: Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 2013; 1: 3.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.